JP2013536244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536244A5 JP2013536244A5 JP2013526123A JP2013526123A JP2013536244A5 JP 2013536244 A5 JP2013536244 A5 JP 2013536244A5 JP 2013526123 A JP2013526123 A JP 2013526123A JP 2013526123 A JP2013526123 A JP 2013526123A JP 2013536244 A5 JP2013536244 A5 JP 2013536244A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- pharmaceutical composition
- patient
- modulator
- egfr inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 229940121647 egfr inhibitor Drugs 0.000 claims 15
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 13
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 claims 13
- 229960001686 afatinib Drugs 0.000 claims 8
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical group N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 102000001301 EGF receptor Human genes 0.000 claims 4
- 108060006698 EGF receptor Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 230000002427 irreversible effect Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37717710P | 2010-08-26 | 2010-08-26 | |
| US61/377,177 | 2010-08-26 | ||
| PCT/US2011/048922 WO2012027445A1 (en) | 2010-08-26 | 2011-08-24 | Methods of administering an egfr inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016252456A Division JP6541637B2 (ja) | 2010-08-26 | 2016-12-27 | Ｅｇｆｒ阻害剤の投与方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013536244A JP2013536244A (ja) | 2013-09-19 |
| JP2013536244A5 true JP2013536244A5 (Direct) | 2014-10-09 |
Family
ID=44583460
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526123A Pending JP2013536244A (ja) | 2010-08-26 | 2011-08-24 | Ｅｇｆｒ阻害剤の投与方法 |
| JP2016252456A Active JP6541637B2 (ja) | 2010-08-26 | 2016-12-27 | Ｅｇｆｒ阻害剤の投与方法 |
| JP2019079787A Pending JP2019147814A (ja) | 2010-08-26 | 2019-04-19 | Ｅｇｆｒ阻害剤の投与方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016252456A Active JP6541637B2 (ja) | 2010-08-26 | 2016-12-27 | Ｅｇｆｒ阻害剤の投与方法 |
| JP2019079787A Pending JP2019147814A (ja) | 2010-08-26 | 2019-04-19 | Ｅｇｆｒ阻害剤の投与方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20130289056A1 (Direct) |
| EP (1) | EP2608792B1 (Direct) |
| JP (3) | JP2013536244A (Direct) |
| CY (1) | CY1119898T1 (Direct) |
| DK (1) | DK2608792T3 (Direct) |
| EC (1) | ECSP13012523A (Direct) |
| ES (1) | ES2655115T3 (Direct) |
| HR (1) | HRP20180016T1 (Direct) |
| HU (1) | HUE038049T2 (Direct) |
| LT (1) | LT2608792T (Direct) |
| NO (1) | NO2608792T3 (Direct) |
| PL (1) | PL2608792T3 (Direct) |
| PT (1) | PT2608792T (Direct) |
| RS (1) | RS56682B1 (Direct) |
| SI (1) | SI2608792T1 (Direct) |
| WO (1) | WO2012027445A1 (Direct) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2770308T3 (es) | 2008-10-02 | 2020-07-01 | Salix Pharmaceuticals Ltd | Procedimientos de tratamiento de encefalopatía hepática |
| NO2608792T3 (Direct) | 2010-08-26 | 2018-03-10 | ||
| BR112021010500A2 (pt) * | 2018-11-30 | 2021-08-24 | Beth Israel Deaconess Medical Center, Inc. | Método para reduzir a p-selectina solúvel em um paciente com câncer, método para reduzir ou prevenir a formação de um trombo em um paciente com câncer, método para promover a regressão tumoral em um paciente com câncer, método para estabilizar ou reduzir o câncer metastático em um paciente com câncer, composição farmacêutica para reduzir a p-selectina solúvel em um paciente com câncer, composição farmacêutica para reduzir ou prevenir a formação de um trombo em um paciente com câncer, composição farmacêutica para promover a regressão tumoral em um paciente com câncer e composição farmacêutica para estabilizar ou reduzir câncer metastático em um paciente com câncer |
| US12403122B2 (en) | 2021-05-19 | 2025-09-02 | Quercis Pharma AG | Method for treating amyotrophic lateral sclerosis using quercetin-containing compositions |
| WO2023288044A1 (en) | 2021-07-16 | 2023-01-19 | Beth Israel Deaconess Medical Center, Inc. | Method for treating sickle cell disease using quercetin-containing compositions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2002087585A1 (en) * | 2001-05-01 | 2002-11-07 | Abbott Laboratories | Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents |
| US20030225079A1 (en) | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
| DE10307165A1 (de) | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20070009533A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism |
| WO2007054550A1 (en) * | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| DK1948180T3 (da) | 2005-11-11 | 2013-05-27 | Boehringer Ingelheim Int | Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer |
| EP1981863B1 (en) | 2006-01-26 | 2012-10-10 | Boehringer Ingelheim International GmbH | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
| NZ576065A (en) | 2006-09-18 | 2011-12-22 | Boehringer Ingelheim Int | Method for treating cancer harboring egfr mutations |
| WO2008121467A2 (en) | 2007-02-28 | 2008-10-09 | Dana-Farber Cancer Institute, Inc. | Combination therapy for treating cancer |
| UY31867A (es) | 2008-06-06 | 2010-01-29 | Boehringer Ingelheim Int | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 |
| PT2451445T (pt) | 2009-07-06 | 2019-07-10 | Boehringer Ingelheim Int | Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo |
| NO2608792T3 (Direct) | 2010-08-26 | 2018-03-10 |
-
2011
- 2011-08-24 NO NO11752700A patent/NO2608792T3/no unknown
- 2011-08-24 PT PT117527002T patent/PT2608792T/pt unknown
- 2011-08-24 EP EP11752700.2A patent/EP2608792B1/en not_active Revoked
- 2011-08-24 PL PL11752700T patent/PL2608792T3/pl unknown
- 2011-08-24 RS RS20171343A patent/RS56682B1/sr unknown
- 2011-08-24 WO PCT/US2011/048922 patent/WO2012027445A1/en not_active Ceased
- 2011-08-24 DK DK11752700.2T patent/DK2608792T3/en active
- 2011-08-24 HU HUE11752700A patent/HUE038049T2/hu unknown
- 2011-08-24 US US13/817,571 patent/US20130289056A1/en not_active Abandoned
- 2011-08-24 SI SI201131382T patent/SI2608792T1/en unknown
- 2011-08-24 LT LTEP11752700.2T patent/LT2608792T/lt unknown
- 2011-08-24 HR HRP20180016TT patent/HRP20180016T1/hr unknown
- 2011-08-24 JP JP2013526123A patent/JP2013536244A/ja active Pending
- 2011-08-24 ES ES11752700.2T patent/ES2655115T3/es active Active
-
2013
- 2013-03-25 EC ECSP13012523 patent/ECSP13012523A/es unknown
-
2016
- 2016-06-09 US US15/177,612 patent/US20160287591A1/en not_active Abandoned
- 2016-12-27 JP JP2016252456A patent/JP6541637B2/ja active Active
-
2018
- 2018-01-09 CY CY20181100024T patent/CY1119898T1/el unknown
-
2019
- 2019-04-19 JP JP2019079787A patent/JP2019147814A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| HRP20190537T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor b-raf, inhibitor egfr i po izboru inhibitor pi3k-alfa | |
| JP2013536244A5 (Direct) | ||
| BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| NZ748451A (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| WO2013048558A3 (en) | Methods of therapeutic monitoring of nitrogen scavenging drugs | |
| MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| WO2012154587A3 (en) | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents | |
| MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
| MX390667B (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| JP2012502103A5 (Direct) | ||
| MX2013012206A (es) | Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas. | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| JP2007119497A5 (Direct) | ||
| HK1243704A1 (zh) | 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案 | |
| NZ588886A (en) | Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level | |
| HK1252411A1 (zh) | 磷脂酰肌醇3-激酶抑制剂的给药方案 | |
| EA201491870A1 (ru) | Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента | |
| WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| MX2013012204A (es) | Metodo para producir substancias con gas sobresaturado, dispositivo de suministro transdermico de las mismas, y usos de las mismas. | |
| UA111123C2 (uk) | Застосування комбінованого терапевтичного засобу для лікування риніту | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |